SPATA20 Inhibitors
Chemical inhibitors of SPATA20 include a variety of compounds that interfere with different signaling pathways and kinase activities which are crucial for the functional activity of the protein. Bisindolylmaleimide I, for instance, is a potent inhibitor of protein kinase C (PKC), and its action can prevent the phosphorylation and subsequent activation of SPATA20, assuming that PKC-mediated phosphorylation is a regulatory mechanism for SPATA20. Similarly, Genistein, by targeting tyrosine kinases, can inhibit the phosphorylation of SPATA20 on tyrosine residues, which is often a key activation step for proteins. LY294002 and Wortmannin both act as inhibitors of phosphoinositide 3-kinases (PI3K), which could lead to a decrease in Akt phosphorylation, a signaling event that might be upstream of SPATA20, thereby reducing its activity. PD98059 and U0126 target the MAPK/ERK pathway by inhibiting MEK.
In a similar vein, SB203580 and SP600125 act on the MAP kinase pathways, with SB203580 specifically targeting p38 MAP kinase and SP600125 inhibiting JNK. Inhibition of these kinases can lead to decreased activity of downstream proteins, potentially including SPATA20. Rapamycin, an inhibitor of mTOR, could also reduce the activity of SPATA20 by diminishing the action of proteins downstream of mTOR that may regulate SPATA20. Y-27632 inhibits the Rho/ROCK pathway, and its action would decrease SPATA20 activity. PP2, by inhibiting Src family tyrosine kinases, can decrease SPATA20 activity. Lastly, ZM 336372, which targets Raf kinase, could lead to a reduction in SPATA20 function. Each of these chemicals offers a strategic point of interference within cellular signaling pathways that could culminate in the inhibition of SPATA20 activity, assuming the protein functions within these contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I acts as a protein kinase C inhibitor, and if SPATA20 is regulated by PKC-mediated phosphorylation, this inhibitor would prevent SPATA20 activation by disrupting its phosphorylation state. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting tyrosine kinases, genistein may prevent the phosphorylation of SPATA20, leading to its functional inhibition as tyrosine phosphorylation can regulate protein activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor. Inhibition of PI3K can lead to a decrease in Akt phosphorylation, which may be involved in SPATA20 function. Reduced Akt activity could diminish SPATA20 activity if SPATA20 is downstream of the PI3K/Akt pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which would inhibit the MAPK/ERK pathway. Inhibition of this pathway may lead to reduced activity of downstream proteins, including SPATA20, if it is regulated by MAPK/ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. If SPATA20 activity relies on p38 MAPK signaling for its function, SB203580 would result in the reduction of SPATA20 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which would prevent the activation of downstream targets of PI3K, potentially including SPATA20, leading to its inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Inhibiting MEK1/2 would prevent ERK activation, potentially inhibiting SPATA20 if it requires MAPK pathway activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which may be involved in the regulation of SPATA20. By inhibiting mTOR, rapamycin could reduce SPATA20 activity by reducing the activity of downstream targets that could include SPATA20. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which, through its influence on the c-Jun pathway, might regulate SPATA20. Inhibition of JNK would, therefore, reduce SPATA20 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, and if SPATA20 function is regulated by the Rho/ROCK pathway, this inhibitor would lead to diminished SPATA20 activity. | ||||||